abstract：:YKL-40, also called chitinase-3-like-1 protein, is an inflammatory biomarker that has been associated with disease severity in inflammatory and malignant diseases, including AML, multiple myeloma and lymphomas. The objective of the current study was to assess the prognostic value of pretransplant recipient and donor p...

journal_title：Bone marrow transplantation

authors： Kornblit B,Wang T,Lee SJ,Spellman SR,Zhu X,Fleischhauer K,Müller C,Verneris MR,Müller K,Johansen JS,Vindelov L,Garred P

更新日期：2016-12-01 00:00:00

abstract：:Jak1/2 inhibitor ruxolitinib is a promising agent for treating steroid-refractory GvHD after allogeneic hematopoietic stem cell transplantation (SCT) to produce quick and durable responses. However, optimal dose and tapering schedule of ruxolitinib remain to be determined. Discontinuation of ruxolitinib in myelofibros...

journal_title：Bone marrow transplantation

authors： Mori Y,Ikeda K,Inomata T,Yoshimoto G,Fujii N,Ago H,Teshima T

更新日期：2016-12-01 00:00:00

abstract：:Driven by access to better drugs, on average, newly diagnosed multiple myeloma patients have over 10 years overall survival. Using modern combination therapies-with or without the addition of high-dose melphalan and autologous stem cell transplantation-up to 80% of patients reach a complete response. As a logical and ...

journal_title：Bone marrow transplantation

authors： Landgren O,Devlin S,Boulad M,Mailankody S

更新日期：2016-12-01 00:00:00

abstract：:Allogeneic hematopoietic cell transplantation (allo-HCT) for patients with AML is increasingly able to impact the historically poor outcomes in this disease. Nonetheless, even with transplant, the rates of post-HCT relapse are unacceptably high, and remain a great challenge in the treatment of patients with AML. Maint...

journal_title：Bone marrow transplantation

authors： Brunner AM,Fathi AT,Chen YB

更新日期：2016-11-01 00:00:00

abstract：:Younger children are considered to be more vulnerable to late effects (LE), which prompted us to study LE in patients after haematopoietic stem cell transplantation (HSCT) for a haematological malignancy before the age of 3. In this multicentre EBMT study, cumulative incidence (CI) and severity of endocrine LE, centra...

journal_title：Bone marrow transplantation

authors： Bresters D,Lawitschka A,Cugno C,Pötschger U,Dalissier A,Michel G,Vettenranta K,Sundin M,Al-Seraihy A,Faraci M,Sedlacek P,Versluys AB,Jenkins A,Lutz P,Gibson B,Leiper A,Diaz MA,Shaw PJ,Skinner R,O'Brien TA,Salooja

更新日期：2016-11-01 00:00:00

abstract：:The extant literature documents burden among caregivers of patients undergoing a hematopoietic stem cell transplantation (HSCT), but little is known about the burden of caregivers of patients receiving outpatient and homebound HSCTs. This scoping study sought to evaluate what is known about the burden of the increasin...

journal_title：Bone marrow transplantation

authors： Applebaum AJ,Bevans M,Son T,Evans K,Hernandez M,Giralt S,DuHamel K

更新日期：2016-11-01 00:00:00

abstract：:Haploidentical hematopoietic stem cell transplantation using T-cell-depleted grafts is a valid option for pediatric patients with hematological malignancies in need of an allogeneic transplantation and lacking an HLA-identical donor. Seventy-five transplantations were performed in 70 patients. Thirty-eight patients ha...

journal_title：Bone marrow transplantation

authors： Diaz MA,Pérez-Martínez A,Herrero B,Deltoro N,Martinez I,Ramirez M,Abad L,Sevilla J,Merino E,Ruiz J,Vicario JL,Gonzalez-Vicent M

更新日期：2016-09-01 00:00:00

abstract：:High-dose chemotherapy (HDC) was investigated in high-risk neuroblastoma (HR-NBL) to reduce the risk of relapse. We report the results of the 30-year experience of a cohort of patients with HR-NBL treated with high-dose (HD) busulfan (Bu)-containing regimens. From 1980 to 2009, 215 patients aged >1 year with stage 4 N...

journal_title：Bone marrow transplantation

authors： Proust-Houdemont S,Pasqualini C,Blanchard P,Dufour C,Benhamou E,Goma G,Semeraro M,Raquin MA,Hartmann O,Valteau-Couanet D

更新日期：2016-08-01 00:00:00

abstract：:Treatment with allogeneic hematopoietic stem cell transplantation (HSCT) is associated with short and long-term toxicities that can result in alterations in sexual functioning. The aims of this prospective evaluation were to determine: (1) associations between HSCT and increased sexual dysfunction 1 year after treatme...

journal_title：Bone marrow transplantation

authors： Noerskov KH,Schjødt I,Syrjala KL,Jarden M

更新日期：2016-06-01 00:00:00

abstract：:Although neurocognitive impairment has been established as a major issue among cancer survivors, the real-world consequences of this impairment are unclear. This study investigated the relationship between neurocognitive functioning and medication management ability over time among 58 patients treated with allogeneic ...

journal_title：Bone marrow transplantation

authors： Mayo S,Messner HA,Rourke SB,Howell D,Victor JC,Kuruvilla J,Lipton JH,Gupta V,Kim DD,Piescic C,Breen D,Lambie A,Loach D,Michelis FV,Alam N,Uhm J,McGillis L,Metcalfe K

更新日期：2016-06-01 00:00:00

abstract：:Adjuvant transfusion of donor lymphocytes (aDLT) may reduce the risk of relapse after allogeneic stem cell transplantation in high-risk AML. We performed a retrospective analysis on the safety and efficacy of aDLT in a cohort of 46 patients. To be eligible for aDLT, patients had to be in CR for at least 120 days from ...

journal_title：Bone marrow transplantation

authors： Jedlickova Z,Schmid C,Koenecke C,Hertenstein B,Baurmann H,Schwerdtfeger R,Tischer J,Kolb HJ,Schleuning M

更新日期：2016-05-01 00:00:00

abstract：:Allogeneic hematopoietic cell transplantation (alloHCT) may be the only curative option for some older adults with hematologic malignancies, and its associated risks of significant morbidity and mortality warrant a clear, informed decision-making process. As older adults have not been transplanted routinely until rece...

journal_title：Bone marrow transplantation

authors： Randall J,Keven K,Atli T,Ustun C

更新日期：2016-05-01 00:00:00

abstract：:Ataxia telangiectasia is a genetic instability syndrome characterized by neurodegeneration, immunodeficiency, severe bronchial complications, hypersensitivity to radiotherapy and an elevated risk of malignancies. Repopulation with ATM-competent bone marrow-derived cells (BMDCs) significantly prolonged the lifespan and...

journal_title：Bone marrow transplantation

authors： Pietzner J,Merscher BM,Baer PC,Duecker RP,Eickmeier O,Fußbroich D,Bader P,Del Turco D,Henschler R,Zielen S,Schubert R

更新日期：2016-04-01 00:00:00

abstract：:In the era of chemoimmunotherapy, the optimal treatment paradigm for relapsed and refractory diffuse large B-cell lymphoma has been challenged. We reviewed the outcome of standard salvage therapy with an autologous stem cell transplant (autoSCT) over the last two decades and the outcome of allogeneic SCT (alloSCT) in ...

journal_title：Bone marrow transplantation

authors： Robinson SP,Boumendil A,Finel H,Blaise D,Poiré X,Nicolas-Virelizier E,Or R,Malladi R,Corby A,Fornecker L,Caballero D,Pohlreich D,Nagler A,Thieblemont C,Finke J,Bachy E,Vincent L,Schroyens W,Schouten H,Dreger P

更新日期：2016-03-01 00:00:00

abstract：:The use of hematopoietic stem cell transplantation or blood and marrow transplantation (BMT) is on the increase worldwide. With BMT's increasing utilization and increasing success, the number of BMT survivors in the United States alone is expected to surpass 500 000 by the year 2030. BMT survivors are susceptible to a...

journal_title：Bone marrow transplantation

authors： Cupit MC,Duncan C,Savani BN,Hashmi SK

更新日期：2016-02-01 00:00:00

abstract：:Among patients with myelodysplastic syndrome (MDS) undergoing hematopoietic cell transplantation (HCT), the impact of residual pretransplant cytogenetically abnormal cells on outcomes remains uncertain. We analyzed HCT outcomes by time of transplant disease variables, including (1) blast percentage, (2) percentage of ...

journal_title：Bone marrow transplantation

authors： Trottier BJ,Sachs Z,DeFor TE,Shune L,Dolan M,Weisdorf DJ,Ustun C,Warlick ED

更新日期：2016-02-01 00:00:00

abstract：:Acute GVHD (aGVHD) is an immunologic complication of allogeneic hematopoietic cell transplantation (HCT) that can range from mild to life-threatening. Models to predict patients at risk of poor outcomes have been developed using both clinical and laboratory data, and the time to test these models in clinical trials ha...

journal_title：Bone marrow transplantation

authors： Holtan SG,MacMillan ML

更新日期：2016-02-01 00:00:00

abstract：:Cord blood (CB) transplantation is an alternate source of human hematopoietic progenitor cells for allogeneic stem cell transplantation in children and adolescents with both malignant and nonmalignant diseases. Current limitations included delay in hematopoietic reconstitution, increased incidence of primary graft fai...

journal_title：Bone marrow transplantation

authors： Cairo MS,Tarek N,Lee DA,Delaney C

更新日期：2016-01-01 00:00:00

abstract：:Hepatic acute GvHD (aGvHD) is associated with high mortality owing to poor response to immunosuppressive therapy. The pathogenesis of hepatic aGvHD differs from that of other lesions, and specific risk factors related to pre-transplant liver conditions should be determined. We conducted a cohort study by using a Japan...

journal_title：Bone marrow transplantation

authors： Arai Y,Kanda J,Nakasone H,Kondo T,Uchida N,Fukuda T,Ohashi K,Kaida K,Iwato K,Eto T,Kanda Y,Nakamae H,Nagamura-Inoue T,Morishima Y,Hirokawa M,Atsuta Y,Murata M,GVHD working group of the Japan Society for Hematopoietic Ce

更新日期：2016-01-01 00:00:00

abstract：:Increased use of novel agents and autologous stem cell transplantation has led to a significant improvement in PFS and overall survival in patients with multiple myeloma. Despite improved treatment strategies, most patients eventually relapse due to persistent low levels of disease in the bone marrow. Increasingly sen...

journal_title：Bone marrow transplantation

authors： Sherrod AM,Hari P,Mosse CA,Walker RC,Cornell RF

更新日期：2016-01-01 00:00:00

abstract：:To elucidate factors contributing to the effectiveness of allogeneic hematopoietic stem cell transplantation (alloHCT) in high-risk CLL, immune interventions, GvHD and clinical outcome of 77 consecutive patients allografted for CLL were analyzed. Immune modulation (immunosuppression tapering, rituximab-augmented donor...

journal_title：Bone marrow transplantation

authors： Hahn M,Böttcher S,Dietrich S,Hegenbart U,Rieger M,Stadtherr P,Bondong A,Schulz R,Ritgen M,Schmitt T,Tran TH,Görner M,Herth I,Luft T,Schönland S,Witzens-Harig M,Zenz T,Kneba M,Ho AD,Dreger P

更新日期：2015-10-01 00:00:00

abstract：:In allo-stem cell transplantation (SCT), it is unclear whether donor-specific anti-HLA Abs (DSAs) can actually mediate graft rejection or if they are simply surrogate markers for the cellular immunity that causes graft rejection. Here, we first analyzed a case of cord blood allograft rejection in which DSA and cytotox...

journal_title：Bone marrow transplantation

authors： Hanajiri R,Murata M,Sugimoto K,Murase M,Sakemura R,Goto T,Watanabe K,Imahashi N,Terakura S,Ohashi H,Akatsuka Y,Kurahashi S,Miyamura K,Kiyoi H,Nishida T,Naoe T

更新日期：2015-09-01 00:00:00

abstract：:Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is an alternative for patients who need a transplant without having conventional donors. One hundred and five consecutive patients with hematologic malignancies who underwent G-CSF-primed peripheral blood haplo-HSCT without in vitro T-cell depletion i...

journal_title：Bone marrow transplantation

authors： Lin X,Lu ZG,Song CY,Huang YX,Guo KY,Deng L,Tu SF,He YZ,Xu JH,Long H,Wu BY

更新日期：2015-08-01 00:00:00

abstract：:Fms-like tyrosine kinase-3 ligand (Flt3L) uniquely binds the Flt3 (CD135) receptor expressed on hematopoietic stem cells (HSCs), early progenitor cells, immature thymocytes and steady-state dendritic cells (DCs) and induces their proliferation, differentiation, development and mobilization in the bone marrow, peripher...

journal_title：Bone marrow transplantation

authors： Anandasabapathy N,Breton G,Hurley A,Caskey M,Trumpfheller C,Sarma P,Pring J,Pack M,Buckley N,Matei I,Lyden D,Green J,Hawthorne T,Marsh HC,Yellin M,Davis T,Keler T,Schlesinger SJ

更新日期：2015-07-01 00:00:00

abstract：:Pretransplant influenza vaccination of the donor or allogeneic hematopoietic SCT (HSCT) candidate was evaluated in a randomized study. One hundred and twenty-two HSCT recipients and their donors were assigned to three randomization groups: no pretransplant vaccination (n=38), donor pretransplant vaccination (n=44) or ...

journal_title：Bone marrow transplantation

authors： Ambati A,Boas LS,Ljungman P,Testa L,de Oliveira JF,Aoun M,Colturato V,Maeurer M,Machado CM

更新日期：2015-06-01 00:00:00

abstract：:Clinical trials have shown that a strategy for haploidentical transplantation based on the infusion of high numbers of T-cell-depleted hematopoietic progenitor cells and no post-transplant immunosuppression controls graft rejection and GvHD in patients with acute leukemia. Overall, event-free survival compares favorab...

journal_title：Bone marrow transplantation

authors： Aversa F

更新日期：2015-06-01 00:00:00

abstract：:Immune recovery was retrospectively analyzed in a cohort of 41 patients with acute leukemia, myelodysplastic syndrome and nonmalignant diseases, who received αβ T- and B-cell-depleted allografts from haploidentical family donors. Conditioning regimens consisted of fludarabine or clofarabine, thiotepa, melphalan and se...

journal_title：Bone marrow transplantation

authors： Lang P,Feuchtinger T,Teltschik HM,Schwinger W,Schlegel P,Pfeiffer M,Schumm M,Lang AM,Lang B,Schwarze CP,Ebinger M,Urban C,Handgretinger R

更新日期：2015-06-01 00:00:00

abstract：:Hematopoietic SCT is currently the only curative therapy for a range of benign inherited and acquired primary hematologic disorders in children, including BM failure syndromes and hemoglobinopathies. The preferred HLA-matched sibling donor is available for only about 25% of such children. However, there has been subst...

journal_title：Bone marrow transplantation

authors： Tolar J,Sodani P,Symons H

更新日期：2015-05-01 00:00:00

abstract：:The role of allogeneic hematopoietic SCT (allo-HCT) in multiple myeloma (MM) remains controversial. A total of 58 patients received an allo-HCT (25 of them with myeloablative conditioning-allo-MAC-and 33 with reduced-intensity conditioning-allo-RIC) at our institution over a 28-year period. The CR rate for allo-MAC wa...

journal_title：Bone marrow transplantation

authors： Rosiñol L,Jiménez R,Rovira M,Martínez C,Fernández-Avilés F,Marín P,Suárez-Lledó M,Gutiérrez-García G,Fernández de Larrea C,Carreras E,Urbano-Ispizua A,Bladé J

更新日期：2015-05-01 00:00:00

abstract：:Outcomes in multiple myeloma (MM) have improved significantly with novel agent therapy and autologous stem cell transplantation (ASCT). ASCTs are typically planned as either tandem or a single transplant with additional stored PBSCs available for a second salvage transplant. To accommodate these strategies, many cente...

journal_title：Bone marrow transplantation

authors： Phipps C,Linenberger M,Holmberg LA,Green D,Becker P,Connelly-Smith L,Klippel Z,Burwick N,Gopal A,Bensinger WI,Libby E

更新日期：2015-05-01 00:00:00

abstract：:The best donors for hematopoietic SCT (HSCT) are fully-matched siblings. In patients without fully-matched siblings, HLA registries or cord blood banks are alternative strategies with some restrictions. Owing to the high rate of consanguineous marriage in our country, between 2006 and 2013, extended family searches we...

journal_title：Bone marrow transplantation

authors： Hamidieh AA,Dehaghi MO,Paragomi P,Navaei S,Jalali A,Eslami GG,Behfar M,Ghavamzadeh A

更新日期：2015-04-01 00:00:00

abstract：:Trial outcomes comparing cytokine agents for PBSC mobilization in autologous hematopoietic transplant patients have been controversial. We performed a systematic review and meta-analysis of evidence available on pegfilgrastim vs filgrastim in chemo-cytokine mobilization. Electronic literature searches of PubMed, EMBAS...

journal_title：Bone marrow transplantation

authors： Kim MG,Han N,Lee EK,Kim T

更新日期：2015-04-01 00:00:00

abstract：:We investigated the prognostic relevance of IKZF1 deletions in 118 adult Ph-positive ALL patients who had minimal residual disease (MRD) data under a uniform treatment of allo-SCT following first-line imatinib-based chemotherapy. IKZF1 deletions were identified in 93 patients (78.8%). IKZF1-deleted patients had a lowe...

journal_title：Bone marrow transplantation

authors： Kim M,Park J,Kim DW,Kim YJ,Jeon YW,Yoon JH,Shin SH,Yahng SA,Lee SE,Cho BS,Eom KS,Kim HJ,Min CK,Cho SG,Kim Y,Lee JW,Han K,Min WS,Lee S

更新日期：2015-03-01 00:00:00

abstract：:Over the past 15 years, SCT has emerged as a promising treatment option for patients with severe autoimmune diseases (ADs). Mechanistic studies recently provided the proof-of-concept that restoration of immunological tolerance can be achieved by haematopoietic SCT in chronic autoimmunity through eradication of the pat...

journal_title：Bone marrow transplantation

authors： Alexander T,Bondanza A,Muraro PA,Greco R,Saccardi R,Daikeler T,Kazmi M,Hawkey C,Simoes BP,Leblanc K,Fibbe WE,Moore J,Snarski E,Martin T,Hiepe F,Velardi A,Toubert A,Snowden JA,Farge D

更新日期：2015-02-01 00:00:00

abstract：:Allo-SCT using unrelated donors is a curative treatment for patients with hematological disorders. The best donor is one matched for 10/10 HLA alleles, however studies have shown an additional survival benefit when considering other genetic factors. It has been shown that a six-nucleotide insertion/deletion polymorphi...

journal_title：Bone marrow transplantation

authors： Shaw BE,Lee F,Krishnamurthy S,Byrne JL,Seedhouse C,Mayor NP,Maldonado-Torres H,Saudemont A,Marsh SG,Madrigal JA,Russell NH

更新日期：2015-02-01 00:00:00

abstract：:Numerous studies have reported the feasibility and safety of autologous SCT (ASCT) in patients with multiple myeloma (MM) and mild to moderate renal impairment, but there are limited data in dialysis-dependent patients. In this retrospective study, we reviewed the toxicities and efficacy outcomes of 33  MM patients wi...

journal_title：Bone marrow transplantation

authors： St Bernard R,Chodirker L,Masih-Khan E,Jiang H,Franke N,Kukreti V,Tiedemann R,Trudel S,Reece D,Chen CI

更新日期：2015-01-01 00:00:00

abstract：:A potential link between arsenic (ATO)-based therapy and delayed hematopoietic recovery after autologous hematopoietic SCT (HSCT) for acute promyelocytic leukemia (APL) has previously been reported. We retrospectively reviewed the clinical histories of 58 patients undergoing autologous HSCT for APL at 21 institutions ...

journal_title：Bone marrow transplantation

authors： Mannis GN,Logan AC,Leavitt AD,Yanada M,Hwang J,Olin RL,Damon LE,Andreadis C,Ai WZ,Gaensler KM,Greene CC,Gupta NK,Kaplan LD,Mahindra A,Miyazaki Y,Naoe T,Ohtake S,Sayre PH,Smith CC,Venstrom JM,Wolf JL,Caballero L

更新日期：2015-01-01 00:00:00

abstract：:In an attempt to reduce the incidence of chronic GVHD (cGVHD) after reduced-intensity conditioning (RIC), we used BM instead of PBSC and added melphalan 100 mg/m(2) to the classical association of fludarabine, 30 mg/m(2)/day for 3 days and TBI, 200 cGy (FLUIM regimen). Between 2000 and 2012, 51 patients received BM wi...

journal_title：Bone marrow transplantation

authors： Gomez E,Duléry R,Langlois C,Coiteux V,Terriou L,Magro L,Gauthier J,de Berranger E,Duhamel A,Yakoub-Agha I

更新日期：2014-12-01 00:00:00

abstract：:Sickle cell anemia (SCA) remains associated with high risks of morbidity and early death. Allogeneic hematopoietic SCT (HSCT) is the only curative treatment for SCA. We report our experience with transplantation in a group of patients with the non-Black African variant and the Black African variant of SCA. This study ...

journal_title：Bone marrow transplantation

authors： Lucarelli G,Isgrò A,Sodani P,Marziali M,Gaziev J,Paciaroni K,Gallucci C,Cardarelli L,Ribersani M,Alfieri C,De Angelis G,Armiento D,Andreani M,Testi M,Amato A,Akinyanju OO,Wakama TT

更新日期：2014-11-01 00:00:00

abstract：:Hematopoietic cell transplantation (HCT) has become an established standard of care for many older patients with hematologic malignancies. The effect of transplantation on the quality of life (QOL) of older patients, however, has not been well studied. We thus analyzed QOL in patients ⩾60 undergoing an allogeneic HCT ...

journal_title：Bone marrow transplantation

authors： Hamilton BK,Rybicki L,Dabney J,McLellan L,Haddad H,Foster L,Abounader D,Kalaycio M,Sobecks R,Dean R,Duong H,Hill BT,Bolwell BJ,Copelan EA

更新日期：2014-11-01 00:00:00